CA2999332A1 - Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease - Google Patents

Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease Download PDF

Info

Publication number
CA2999332A1
CA2999332A1 CA2999332A CA2999332A CA2999332A1 CA 2999332 A1 CA2999332 A1 CA 2999332A1 CA 2999332 A CA2999332 A CA 2999332A CA 2999332 A CA2999332 A CA 2999332A CA 2999332 A1 CA2999332 A1 CA 2999332A1
Authority
CA
Canada
Prior art keywords
methyl
compound
mmol
dihydroisoquinolin
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2999332A
Other languages
English (en)
French (fr)
Inventor
Gregory Alan Stephenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2999332A1 publication Critical patent/CA2999332A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2999332A 2015-10-23 2016-10-18 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease Abandoned CA2999332A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245391P 2015-10-23 2015-10-23
US62/245,391 2015-10-23
PCT/US2016/057447 WO2017070068A1 (en) 2015-10-23 2016-10-18 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
CA2999332A1 true CA2999332A1 (en) 2017-04-27

Family

ID=57233858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2999332A Abandoned CA2999332A1 (en) 2015-10-23 2016-10-18 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease

Country Status (13)

Country Link
CN (1) CN108137506A (zh)
AR (1) AR106332A1 (zh)
AU (1) AU2016341115A1 (zh)
CA (1) CA2999332A1 (zh)
DO (1) DOP2018000103A (zh)
EA (1) EA201890525A1 (zh)
EC (1) ECSP18030976A (zh)
IL (1) IL257872A (zh)
MX (1) MX2018004794A (zh)
PE (1) PE20181296A1 (zh)
PH (1) PH12018500859A1 (zh)
TW (1) TW201725199A (zh)
WO (1) WO2017070068A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
MA54530A (fr) * 2018-12-18 2021-10-27 Lilly Co Eli Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques
TWI843678B (zh) * 2019-06-18 2024-05-21 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
US20240299375A1 (en) 2021-03-08 2024-09-12 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
MX2023010542A (es) 2021-03-09 2023-11-24 Lilly Co Eli Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.
CN113264926A (zh) * 2021-05-31 2021-08-17 东北林业大学 一种牡荆素与利血平的共晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
AU2008223145A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine H3 receptor
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
CN108137506A (zh) 2018-06-08
ECSP18030976A (es) 2018-05-31
PE20181296A1 (es) 2018-08-07
DOP2018000103A (es) 2018-10-31
AR106332A1 (es) 2018-01-03
WO2017070068A1 (en) 2017-04-27
TW201725199A (zh) 2017-07-16
PH12018500859A1 (en) 2018-10-29
AU2016341115A1 (en) 2018-04-12
EA201890525A1 (ru) 2018-09-28
IL257872A (en) 2018-06-03
MX2018004794A (es) 2018-06-19

Similar Documents

Publication Publication Date Title
AU2016238934B2 (en) 3,4-dihydroisoquinolin-2(1H)-yl compounds
CA2999332A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease
JP7034941B2 (ja) Ｌｓｄ１／ｈｄａｃ二重阻害剤としてのシクロプロピル－アミド化合物
CN105764905B (zh) 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基
JP2019503385A (ja) Ｒｏｒ−ガンマのモジュレータとしてのベンズイミダゾール誘導体
WO2018181345A1 (ja) 複素環化合物
US20230322797A1 (en) Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
CA3097692C (en) Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators
AU2016369523B2 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
WO2016011195A1 (en) Th-302 solid forms and methods related thereto
WO2021129629A1 (zh) Zeste增强子同源物2抑制剂及其用途
WO2023078271A1 (zh) 芳香化合物、其制备方法、中间体、药物组合物和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180320

FZDE Discontinued

Effective date: 20191018